{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22","upperLimit":"45","value":"32"},{"groupId":"OG001","lowerLimit":"38","upperLimit":"63","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Any grade acute graft vs host disease (defined in APPENDIX II study protocol).","dispersionType":"95% Confidence Interval","groups":[{"description":"Tacro-MTX/Sirolimus GVHD Prophylaxis","id":"OG000","title":"Experiemental"},{"description":"Tacro-MTX GVHD Prophylaxis","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"2 ineligible patients on experimental arm excluded from analysis. Definition of Acute GVHD: APPENDIX II: COG STEM CELL COMMITTEE CONSENSUS GUIDELINES FOR ESTABLISHING ORGAN STAGE AND OVERALL GRADE OF ACUTE GRAFT VERSUS HOST DISEASE (GVHD) page 90-96 protocol.","reportingStatus":"POSTED","timeFrame":"At 200 days","title":"Estimated Rate of Acute Graft VS Host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}